cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1357Research ArticleДИСЛИПОПРОТЕИДЕМИИВзаимосвязь инсулинорезистентности и показателей липид-транспортной системы при нормогликемии натощакInsulin resistance and lipid transport system in fasting normoglycemiaАлександровичО. В.AlexandrovichO. V.oganov@gnicpm.ruОзероваИ. Н.OzerovaI. N.oganov@gnicpm.ruПероваН. В.PerovaN. V.oganov@gnicpm.ruМетельскаяВ. А.MetelskayaV. A.oganov@gnicpm.ruОлферьевА. М.OlferyevA. M.oganov@gnicpm.ruЩукинаГ. Н.ShchukinaG. N.oganov@gnicpm.ruФГУ Государственный научно-исследовательский центр профилактической медицины РосздраваState Research Center for Preventive Medicine, State Federal Agency for Health and Social DevelopmentМосковский государственный медико-стоматологический университет, МоскваMoscow State Medico-Stomatological University, Moscow200720102007656469Copyright © Александрович О.В., Озерова И.Н., Перова Н.В., Метельская В.А., Олферьев А.М., Щукина Г.Н., 20072007Александрович О.В., Озерова И.Н., Перова Н.В., Метельская В.А., Олферьев А.М., Щукина Г.Н.Alexandrovich O.V., Ozerova I.N., Perova N.V., Metelskaya V.A., Olferyev A.M., Shchukina G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1357

Цель. Выяснить, как связаны показатели инсулинорезистентности (ИР) и липид-транспортной системы (ЛТС) у пациентов с нормогликемией натощак. Материал и методы. У 39 пациентов 20-70 лет с нормальной концентрацией глюкозы в крови натощак определены уровни липидов и аполипопротеинов (апо), а также показатели ИР: индекс инсулиночувствительности и индекс UP (ISI McAuley, HOMA-IR). Результаты. Пациенты с нормогликемией натощак и низким ISI McAuley имели атерогенную дислипопротеидемию: более высокие уровни триглицеридов, апо В, апо В/апо АI, меньший размер частиц липопротеинов низкой плотности; изменения показателей липопротеинов высокой плотности (ЛВП)-опосредованного транспорта холестерина (ХС): более низкий уровень свободного и эстерифицированного ХС ЛВП, фосфолипидов, апо А1, меньшую загруженность частиц ЛВП ХС и более высокое концентрационное отношение апо АII/апо AI. Заключение. У пациентов с нормальным уровнем глюкозы натощак выявление скрытых нарушений углеводного обмена, ассоциированных с изменениями ЛТС, которые могут способствовать развитию ишемической болезни сердца и сахарного диабета 2 типа, позволит начать коррекцию метаболических нарушений на ранних стадиях этих заболеваний.

Aim. To investigate the link between insulin resistance (IR) and lipid transport system in patients with fasting normoglycemia. Material and methods. In 39 patients aged 2070 years, with fasting normoglycemia, the levels of lipids, apolipoproteins (apo), and IR parameters (insulin sensitivity index; ISI McAuley, HOMA-IR) were measured. Results. In patients with fasting normoglycemia and low ISI McAuley, atherogenic dyslipoproteinemia was observed: increased triglycerides, apo B, apo B/apo AI levels, reduced low-density lipoprotein particle size; disturbed high-density lipoprotein (HDL)-mediated cholesterol (CH) transport: reduced levels of free and esterified HDL-CH, phospholipids, apo A1, decreased HDL-CH particle loading, increased apo AII/apo AI concentration ratio. Conclusion. In patients with fasting normoglycemia, diagnosing latent carbohydrate metabolism disturbances, which are associated with lipid transport system abnormalities and potentially increased risk of coronary heart disease or Type 2 diabetes mellitus, provides an opportunity for early metabolic correction.

инсулинорезистентностьдислипопротеидемиялипид-белковые компоненты липипротеинов высокой плотностинормогликемияinsulin resistancedyslipoproteinemiaHDL lipid-protein componentsnormoglycemiaReferencesWeyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000; 24: 89-94.Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000; 24: 89-94.Jensen CC, Cnop M, Hull RL, et al. β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-8.Jensen CC, Cnop M, Hull RL, et al. β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-8.McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001: 24(3): 460-4.McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001: 24(3): 460-4.Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000; 101: 975-80.Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000; 101: 975-80.Evans M, Khan N, Rees A. Diabetic dyslipidaemia and coronary heart disease: new perspectives. Curr Opin Lipidol 1999; 10(5): 387-91.Evans M, Khan N, Rees A. Diabetic dyslipidaemia and coronary heart disease: new perspectives. Curr Opin Lipidol 1999; 10(5): 387-91.Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28(10): 2472-9.Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28(10): 2472-9.Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl): S11-20.Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl): S11-20.Lewis GF, Rader DJ. New Insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.Lewis GF, Rader DJ. New Insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.Yancey PG, Bortnic AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-9.Yancey PG, Bortnic AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-9.Rye K-A, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-8.Rye K-A, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-8.Rashid Sh, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetic studies in humans? J Lipid Res 2006; 47(8): 1631-42.Rashid Sh, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetic studies in humans? J Lipid Res 2006; 47(8): 1631-42.Rye K-A, Clay MA, Barter PJ. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227- 38.Rye K-A, Clay MA, Barter PJ. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227- 38.Cheung M, Sihley Sh, Palmer JP, et al. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-II). J Lipid Res 2003; 44: 1552-8.Cheung M, Sihley Sh, Palmer JP, et al. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-II). J Lipid Res 2003; 44: 1552-8.Lamarch B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance o HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-9.Lamarch B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance o HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-9.Asztalos BF, Rohein PS, Milani RL, et al. Distribution of apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-6.Asztalos BF, Rohein PS, Milani RL, et al. Distribution of apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-6.Borggreve SE., De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33(12): 1051-69.Borggreve SE., De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33(12): 1051-69.Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50(8): 1851-6.Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50(8): 1851-6.Svannborg A, Svennercholm L. Plasma total lipid cholesterol, triglycerides, phosphlipids and free fatty acids in a healthy scandinavian population. Acta Med Scand 1961; 169: 43-6.Svannborg A, Svennercholm L. Plasma total lipid cholesterol, triglycerides, phosphlipids and free fatty acids in a healthy scandinavian population. Acta Med Scand 1961; 169: 43-6.de la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux; relations between serum components and efflux, esterification and transfer. Arterioscler Thromb 1994; 14: 1056- 65.de la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux; relations between serum components and efflux, esterification and transfer. Arterioscler Thromb 1994; 14: 1056- 65.Wallace NM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.Wallace NM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.Соколов Е.И., Александрович О.В., Щельцына Н.В. и др. Субфракционный спектр ЛПНП при абдоминальном и глютеофеморальном ожирении. Бюлл экспер биол мед 2003;11: 513-5.Соколов Е.И., Александрович О.В., Щельцына Н.В. и др. Субфракционный спектр ЛПНП при абдоминальном и глютеофеморальном ожирении. Бюлл экспер биол мед 2003;11: 513-5.Ooi EM, Watts GF, Ji J, et al. Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clin Endocrinol 2006; 65(6): 752-9.Ooi EM, Watts GF, Ji J, et al. Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clin Endocrinol 2006; 65(6): 752-9.Александрович О.В., Озерова И.Н., Олферьев А.М. и др. Ассоциация уровня аполипопротеина А II сыворотки крови с комбинированной гиперлипидемией и нарушенной толерантностью к глюкозе. Бюлл экспер биол мед 2006; 6: 625-8.Александрович О.В., Озерова И.Н., Олферьев А.М. и др. Ассоциация уровня аполипопротеина А II сыворотки крови с комбинированной гиперлипидемией и нарушенной толерантностью к глюкозе. Бюлл экспер биол мед 2006; 6: 625-8.Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of Lp A-I:A-II particles and phospholipid tranfer protein. Atherosclerosis 1996; 127: 245-53.Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of Lp A-I:A-II particles and phospholipid tranfer protein. Atherosclerosis 1996; 127: 245-53.Huuskonen J, Olkkonen VM, Jauhiainen M, et al. The impact of phospholipid tranfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155: 269-81.Huuskonen J, Olkkonen VM, Jauhiainen M, et al. The impact of phospholipid tranfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155: 269-81.Dullaart RP, van Tol A. Role of phospholipids transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab 2001; 61(1): 69-74.Dullaart RP, van Tol A. Role of phospholipids transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab 2001; 61(1): 69-74.Boucher J, Ramsamy TA, Braschi S, et al. Apolipoprotein A II regulates HDL stability and affects hepatic lipase association and activity. J Lipid Res 2004; 45: 849-58.Boucher J, Ramsamy TA, Braschi S, et al. Apolipoprotein A II regulates HDL stability and affects hepatic lipase association and activity. J Lipid Res 2004; 45: 849-58.Rye K-A, Wee K, Curtiss LK, et al. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003; 278: 22530-6.Rye K-A, Wee K, Curtiss LK, et al. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003; 278: 22530-6.Caiazza D, Jahangiri A, RaderDJ, et al. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry 2004; 43: 11898-905.Caiazza D, Jahangiri A, RaderDJ, et al. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry 2004; 43: 11898-905.Hime NJ, Barter PJ, Rye K-A. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 1998; 273(42): 27191-8.Hime NJ, Barter PJ, Rye K-A. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 1998; 273(42): 27191-8.

The authors declare that there are no conflicts of interest present.